Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From China With IO: Lilly Bets $1bn+ To Take Innovent Drug Global

Chinese Firm To Internationalize Via Wider Partnership

Executive Summary

Lilly is acquiring exclusive global rights to a Chinese domestically developed immuno-oncology drug in one of the year’s biggest commercial deals in the country.

You may also be interested in...



BeiGene’s PD-1 Remains Solid In First Global Pivotal Study

Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.

Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor

New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.

Asia Deal Watch: Takeda Will Employ Engitix’s ECM Tech In Liver Fibrosis Indications

Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel